887471-62-7

Upstream product

• 887471-65-0 (S)-4'-(HO)-DADFT-PE iPrE 
• 847829-15-6 ethyl (S)-2-(2,4-dihydroxyphenyl)-4,5-dihydro-4-methyl-4-thiazolecarboxylate 
• 62921-74-8 2-(2-(2-methoxyethoxy)ethoxy)ethyl p-toluenesulfonate 
• 239101-33-8 deferitrin 
• 887471-66-1 ethyl (S)-4,5-dihydro-2-[2-hydroxy-4-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate 
• 887471-64-9 isopropyl (S)-2-(2,4-dihydroxyphenyl)-4,5-dihydro-4-methyl-4-thiazolecarboxylate 

Downstream Products

• 1204750-18-4 2,6-diammoniohexanoic acid (S)-2-(2-hydroxy-4-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)phenyl)-4-methyl-4,5-dihydrothiazole-4-carboxylate 
• 1204750-19-5 2,3,4,5,6-pentahydroxy-N-methylhexan-1-aminium (S)-2-(2-hydroxy-4-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)phenyl)-4-methyl-4,5-dihydrothiazole-4-carboxylate 
• 1204750-20-8 1,3-dihydroxy-2-(hydroxymethyl)propan-2-aminium (S)-2-(2-hydroxy-4-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)phenyl)-4-methyl-4,5-dihydrothiazole-4-carboxylate 
• 887471-66-1 ethyl (S)-4,5-dihydro-2-[2-hydroxy-4-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate 

Relevant academic research and scientific papers

METHOD FOR PRODUCING OPTICALLY ACTIVE DIHYDROTHIAZOLECARBOXYLIC ACID DERIVATIVE

PROBLEM TO BE SOLVED: To provide a method for producing an optically active dihydrothiazolecarboxylic acid derivative, useful as a pharmaceutical, by a short process without using a reagent having genetic toxicity. SOLUTION: The method for producing an optically active dihydrothiazolecarboxylic acid derivative represented by formula (4) comprises: producing an optically active dihydrothiazole ester derivative by reacting (S)-4,5-dihydro-2-(2,4-dihydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid and a glycol monomethyl ether derivative in the presence of a base; and hydrolyzing the same. This is a production method of a dihydrothiazolecarboxylic acid derivative, useful as a pharmaceutical, which enables production of the same by a short process without using a reagent having genetic toxicity and reduces by-production of impurities. SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

DESAZADESFERROTHIOCIN AND DESAZADESFERROTHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS

Disclosed herein are new compounds of desazadesferrothiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.

DESFERRITHIOCIN POLYETHER ANALOGUES

A relatively non-toxic desazadesferrithiocin analog having the formula (I): wherein: R1, R2, R4 and R5 may be the same or different and may be H, straight or branched chain alkyl having up to 14 carbon atoms, e.

Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues

A series of iron-clearing efficiencies (ICEs), ferrokinetics, and toxicity studies for (S)-2-(2,4-dihydroxyphenyl)-4,5-dihydro-4-methyl-4- thiazolecarboxylic acid (deferitrin, 1), (S)-4,5-dihydro-2-[2-hydroxy-4-(3,6,9- trioxadecyloxy)phenyl]-4-methyl-4-th

(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: A solution to nephrotoxicity

Previous studies revealed that within a family of ligands the more lipophilic chelators have better iron-clearing efficiency. The larger the log Papp value of the compound, the better the iron-clearing efficiency. What is also clear from the da

DESFERRITHIOCIN POLYETHER ANALOGUES

Compounds represented by structural formulas described herein, such as Structural Formula (I): are useful in treating conditions such as metal overload, oxidative stress, and neoplastic and preneoplastic conditions.